FY2019 Earnings Forecast for Sage Therapeutics, Inc. Issued By Leerink Swann (SAGE)

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at Leerink Swann reduced their FY2019 earnings per share (EPS) estimates for shares of Sage Therapeutics in a report released on Thursday. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will post earnings per share of ($4.17) for the year, down from their prior estimate of ($2.80). Leerink Swann currently has a “Positive” rating and a $123.00 target price on the stock.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.01. Sage Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year.

WARNING: “FY2019 Earnings Forecast for Sage Therapeutics, Inc. Issued By Leerink Swann (SAGE)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3032632/fy2019-earnings-forecast-for-sage-therapeutics-inc-issued-by-leerink-swann-sage.html.

A number of other equities research analysts have also issued reports on the company. J P Morgan Chase & Co dropped their price target on Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a research report on Tuesday, September 12th. Canaccord Genuity dropped their price target on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a research report on Tuesday, September 12th. Needham & Company LLC dropped their price target on Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, September 13th. SunTrust Banks, Inc. restated a “buy” rating and issued a $82.00 price target (down from $95.00) on shares of Sage Therapeutics in a research report on Wednesday, September 13th. Finally, BMO Capital Markets upped their price target on Sage Therapeutics from $80.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, September 14th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $99.86.

Sage Therapeutics (NASDAQ:SAGE) traded down $1.39 during mid-day trading on Monday, hitting $94.65. The stock had a trading volume of 861,500 shares, compared to its average volume of 525,747. Sage Therapeutics has a 1-year low of $44.55 and a 1-year high of $99.80.

Large investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares in the last quarter. Hershey Trust Co. acquired a new position in Sage Therapeutics during the third quarter worth $118,000. Oppenheimer Asset Management Inc. lifted its stake in Sage Therapeutics by 412.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,565 shares in the last quarter. Turner Investments LLC acquired a new position in Sage Therapeutics during the second quarter worth $159,000. Finally, Dubuque Bank & Trust Co. acquired a new position in Sage Therapeutics during the second quarter worth $167,000.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.